Abcourt Mines Inc. reported a net loss of $28.1 million for the fiscal year ended June 30, 2026, reflecting increased costs as the company began developing its Sleeping Giant gold mine in Quebec. Revenues for the year reached $16.6 million, but mining operations incurred significant losses due to high costs and exploration expenses. The company secured financing with Glencore AG and improved its working capital to $7.5 million, supporting ongoing development and future production preparations. This marks a transition from exploration to development, signaling potential future production growth.
Abcourt Mines Inc. reported a net loss of $28.1 million for the fiscal year ended June 30, 2026, alongside revenues of $16.6 million as it developed its Sleeping Giant gold mine. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 23, 2026 03:21 WIB: out of 83 priced US stocks, 19 rose and 64 fell. Notable movers include AYA at USD 24.00 with a 1-day change of -9.74% and 100% sell order activity, ESI at USD 33.02 down 9.12%, and WDFC at USD 209.45 up 8.77%.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Lycia Therapeutics, a biotech company developing therapies targeting disease-causing proteins, priced its upsized initial public offering at $18 per share, raising approximately $317.5 million before expenses. The company plans to use the funds to ad...
